Inhibitors of human immunodeficiency virus integration

Advances in Antiviral Drug Design

Volumn 4, Issue C, 2003, Pages 63-77

  Hazuda, Daria J ^a   Young, Steven D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956817497     PISSN: 10758593     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1075-8593(03)04002-4     Document Type: Review

References (53)

1. For recent reviews on HIV-1 reverse transcriptase inhibitors, see. Hogberg M., and Morrison I. Expert Opin. Ther. Patents 10 (2000) 1189-1199
2. Jonckheere H., Anné J., and De Clercq E. Med. Res. Rev. 20 (2000) 129-154
3. For recent review on HIV-1 protease inhibitors, see. Lebon F., and Ledecq M. Curr. Med. Chem. 7 (2000) 455-477
4. Vacca J.P., and Condra J.H. Drug Discov. Today 2 (1997) 261-272
5. Palella Jr. F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Ashman D.J., and Holmberg S.D. N. Engl. J. Med. 338 (1998) 853-860
6. Richman D.D. Nature 410 (2001) 995-1001
7. For recent reviews on HIV-1 integrase, see. Esposito D., and Craigie R. Adv. Virus Res. 52 (1999) 319-333
8. Asante-Appiah E., and Skalka A.M. Adv. Virus Res. 52 (1999) 351-369
9. Cai M., Zheng R., Caffrey M., Craigie R., Clore G.M., and Gronenborn A.M. Nat. Struct. Biol. 4 (1997) 567-577
10. Lodi P.J., Ernstn J.A., Kuszewski J., Hickman A.B., Engelman A., Craigie R., Clore G.M., and Gronenborn A.M. Biochemistry 34 (1995) 9826-9833
11. Dyda F., Hickman A.B., Jenkins T.M., Engelman A., Craigie R., and Davies D.R. Science 266 (1994) 1981-1986
12. Cowen J.A. Chem. Rev. 98 (1998) 1067-1087
13. Goldgur Y., Dyda F., Hickman A.B., Jenkins T.M., Craigie R., and Davies D.R. Proc. Natl. Acad. Sci. USA 95 (1998) 9150-9154
14. Drelich M., Wilhelm R., and Mous J. Virology 188 (1992) 459-468
15. Engelman A., and Craigie R. J. Virol. 66 (1992) 6361-6369
16. Kulkosky J., Jones K.S., Katz R.A., Mack J.P., and Skalka A.M. Mol. Cell. Biol. 12 (1992) 2331-2338
17. Wolfe A.L., Felock P.J., Hastings J.C., Blau C.U., and Hazuda D.J. J. Virol. 70 (1996) 1424-1432
18. Asante-Appiah E., and Skalka A.M. J. Biol. Chem. 272 (1997) 16196-16205
19. Hazuda D.J., Felock P.J., Hastings J.C., Pramanik B., and Wolfe A.L. J. Virol. 71 (1997) 7005-7011
20. Ellison V., and Brown P.O. Proc. Natl. Acad. Sci. USA 91 (1994) 7316-7320
21. Vink C., Lutzke R.A., and Plasterk R.H. Nucleic Acids Res. 22 (1994) 4103-4110
22. Pluymers W., Neamati N., Pannecouque C., Fikkert V., Marchand C., Burke T.R., Pommier Y., Schols D., De Clercq E., Debyser Z., and Witvrouw M. Mol. Pharmacol. 58 (2000) 641-648
23. Jing N., Marchand C., Liu J., Mitra R., Hogan M.E., and Pommier Y. J. Biol. Chem. 275 (2000) 21460-21467
24. Esté J.A., Cabrera C., Schols D., Cherepanov P., Gutierrez A., Witvrouw M., Pannecouque C., Debyser Z., Rando R.F., Clotet B., Desmyter J., and De Clercq E. Mol. Pharmacol. 53 (1998) 340-345
25. Pommier Y., and Neamati N. Adv. Virus Res. 52 (1999) 427-458
26. Neamati N. Expert Opin. Invest. Drugs 10 (2001) 281-296
27. Pommier Y., Marchand C., and Neamati N. Antiviral Res. 47 (2000) 139-148
28. Young S.D. Curr. Opin. Drug Discov. Dev. 4 (2001) 402-410
29. Hazuda D.J., Felock P., Witmer M., Wolfe A., Stillmock K., Grobler J.A., Espeseth A., Gabryelski L., Schleif W., Blau C., and Miller M.D. Science 287 (2000) 646-650
30. Hazuda D., Felock P.J., Hastings J.C., Pramanik B., and Wolfe A.L. Drug Des. Discov. 15 (1997) 17-24
31. Hazuda D.J., Felock P.J., Hastings J.C., Pramanik B., and Wolfe A.L. J. Virol. 71 (1997) 7005-7011
32. Farnet C.M., Wang B., Lipford J.R., and Bushman F.D. Proc. Natl. Acad. Sci. USA 93 (1996) 9742-9747
33. Espeseth A., Felock P., Wolfe A., Witmer M., Grobler J., Anthony N., Egbertson M., Melamed J.Y., Young S., Hamill T., Cole J.L., and Hazuda D.J. Proc. Natl. Acad. Sci. USA 97 (2000) 11244-11249
34. Butler S.L., Hansen M.S., and Bushman F.D. Nat. Med. 7 (2001) 631-634
35. Pluymers W., Pais G., Van Maele B., Pannecouque C., Fikkert V., Burke Jr. T.R., De Clercq E., Witvrouw M., Neamati N., and Debyser Z. Antimicrob. Agents Chemother. 46 (2002) 3292-3297
36. Li L., Olvera J.M., Yoder K.E., Mitchell R.S., Butler S.L., Lieber M., Martin S.L., and Bushman F.D. EMBO J. 20 (2001) 3272-3281
37. Daniel R., Katz R.A., and Skalka A.M. Science 284 (1999) 644-647
38. Sharkey M.E., Teo I., Greenough T., Sharova N., Luzuriaga K., Sullivan J.L., Bucy R.P., Kostrikis L.G., Haase A., Veryard C., Davaro R.E., Cheeseman S.H., Daly J.S., Bova C., Ellison III R.T., Mady B., Lai K.K., Moyle G., Nelson M., Gazzard B., Shaunak S., and Stevenson M. Nat. Med. 6 (2000) 76-81
39. Engelman A., Englund G., Orenstein J.M., Martin M.A., and Craigie R. J. Virol. 69 (1995) 2729-2736
40. Wiskerchen M., and Muesing M.A. J. Virol. 69 (1995) 376-386
41. Grobler J.A., Stillmock K., Hu B., Witmer M., Felock P., Espeseth A.S., Wolfe A., Egbertson M.S., Bourgeois M., Melamed J.Y., Wai J.S., Young S.D., Vacca J.P., and Hazuda D.J. Proc. Natl. Acad. Sci. USA 99 (2002) 6661-6666
42. Chow S.A., Vincent K.A., Ellison V., and Brown P.O. Science 255 (1992) 723-726
43. Goldgur Y., Craigie R., Cohen G.H., Fujiwara T., Yoshinaga T., Fujishita T., Sugimoto H., Endo T., Murai H., and Davies D.R. Proc. Natl. Acad. Sci. USA 96 (1999) 13040-13043
44. Bujacz G., Alexandratos J., Wlodawer A., Merkel G., Andrake M., Katz R.A., and Skalka A.M. J. Biol. Chem. 272 (1997) 18161-18168
45. Shaw-Reid C.A., Munshi V., Graham P., Wolfe A., Witmer M., Danzeisen R., Olsen D.B., Carroll S.S., Embrey M., Wai J.S., Miller M.D., Cole J.L., and Hazuda D.J. J. Biol. Chem. 278 (2003) 2777-2780
46. Wai J.S., Egbertson M.S., Payne L.S., Fisher T.E., Embrey M.W., Tran L.O., Melamed J.Y., Langford H.M., Guare Jr. J.P., Zhuang L., Grey V.E., Vacca J.P., Holloway M.K., Naylor-Olsen A.M., Hazuda D.J., Felock P.J., Wolfe A.L., Stillmock K.A., Schleif W.A., Gabryelski L.J., and Young S.D. J. Med. Chem. 43 (2000) 4923-4926
47. (b) Merck & Co., Inc. (Selnick, H.G.; Hazuda, D.J.; Egbertson, M.S.; Guare, J.P.; Wai, J.S.; Young, S.D.; Clark, D.L.; Medina, J.C.). Novel heteroaryl dioxobutyric acid derivatives useful for the treatment of AIDS, WO99/62513 (1999)
48. (a) Payne, L.S.; Tran, L.O.; Zhuang, L.; Young, S.D.; Egbertson, M.S.; Wai, J.S.; Embrey, M.W.; Fisher, T.E.; Guare, J.P.; Langford, H.M.; Melamed, J.Y.; Clark, D.L. Preparation of 1,3-diaryl-1,3-propanediones as HIV integrase inhibitors. Patent WO0100578 A1 (Merck & Co., Inc., USA; Tularik, Inc.)
49. (a) Fujishita, T.; Yoshinaga, T.; Sato, A. Preparation of aromatic heterocycle compounds having HIV integrase inhibiting activities. Patent written in Japanese. Patent WO0039086 A1 (Shionogi & Co., Ltd., Japan)
50. (b) Shionogi & Co., Ltd. (Endoh, T.; Kawata, K.; Nagai, M.; Uenaka, M.). Preparation of new and known 2-acyl-5-benzylfuran, 1,2,4-triazole carboxylic acid ester and 3-(1,2,4-triazol-3-yl)propenone anti-HIV agents by reacting 2-acylfuran compound with benzylhalide. WO00/75122 (2000)
51. (c) Merck & Co., Inc. (Payne, L.S.; Tran, L.; Zhuang, L.H.; Young, S.D.; Egbertson, M.S.; Wai, J.S.; Embrey, M.W.; Fisher, T.E.; Guare, J.P.). 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic-substituted)-1,3-propanediones and their uses as HIV integrase inhibitors. WO01/00587, 2001
52. Hazuda, D.; Schleif, W. Unpublished observations
53. Zhuang L., Wai J.S., Embrey M.W., Fisher T.E., Egbertson M.S., Payne L.S., Guare Jr. J.P., Vacca J.P., Hazuda D.J., Felock P.J., Wolfe A.L., Stillmock K.A., Witmer M.V., Moyer G., Schleif W.A., Gabryelski L.J., Leonard Y.M., Lynch Jr. J.J., Michelson S.R., and Young S.D. J. Med. Chem. 46 (2003) 453-456